Determinants of Treatment Failure and Safety Profile of Extracorporeal Shock Wave Lithotripsy for Upper Urinary Tract Stones: A Secondary Analysis of a Retrospective Cohort of 941 Patients With Risk Stratification and Decision Curve Analysis
Health Innovation Reports · 2026-04-15 · 2 (2) · 4-17
DOI: 10.64048/hir.v2n2.002 ↗Abstract
Background and aim: Extracorporeal shock wave lithotripsy (ESWL) remains a widely used non-invasive treatment for upper urinary tract stones, yet many patients experience treatment failure, retreatment, auxiliary procedures or complications. This study identified their determinants and developed a simple risk-stratification tool evaluated with decision curve analysis.Methods: This secondary analysis of a publicly archived retrospective cohort included 941 patients treated with piezoelectric ESWL for renal or proximal ureteral stones at a single centre (2018–2023). Treatment failure was defined as residual fragments larger than 4 mm at three months. Hierarchical multivariable logistic regression, bootstrap internal validation and decision curve analysis were employed.Results: Stone clearance was achieved in 734 patients (78.0%), whereas 207 (22.0%) experienced treatment failure; 178 (18.9%) needed retreatment, 97 (10.3%) required an auxiliary procedure and 47 (5.0%) developed complications. Stone size greater than 10 mm predicted failure (adjusted odds ratio [aOR] = 1.52), and density above 739 Hounsfield units predicted retreatment (aOR = 1.77). Skin-to-stone distance (aOR = 1.21 per cm) and pre-ESWL double-J stenting (aOR = 2.49) predicted auxiliary procedures, while anticoagulant therapy (aOR = 6.06), hypertension (aOR = 3.78) and female sex (aOR = 2.17) predicted complications. A four-item stone score stratified composite unfavourable outcomes from 31.6% to 58.3%, with modest discrimination (optimism-corrected AUC = 0.578).Conclusions: Stone-related characteristics determined ESWL efficacy, whereas anticoagulant therapy, hypertension and female sex determined its safety. A simple stone score can support pre-treatment counselling, but external validation is required before it guides treatment selection.
EUVIMED